TONABERSAT Chemical Properties

Boiling point:

554.5±50.0 °C(Predicted)

Density 

1.38

storage temp. 

2-8°C

solubility 

Soluble in DMSO

pka

11.86±0.60(Predicted)

form 

powder

color 

white to beige

optical activity

[α]/D -100 to -110°, c = 1 in methanol

Safety Information

RIDADR 

UN 3077 9 / PGIII

TONABERSAT Usage And Synthesis

Uses

It is a cholinesterase inhibitor for treating and preventing migraine. An antimigraine agent.

Biological Activity

migraine is a common, recurrent and primary headache disorder. optimisation of novel cis- and trans-4-(substituted-anfido)benzopyran-3-ol derivatives has led to the identification of tonabersat (sb-220453) with potential antimigraine activity.

Biochem/physiol Actions

Tonabersat (SB-220453) exhibits anticonvulsant property. It is a member of the family of novel benzoylamino-benzopyran compounds. Tonabersat is used as a therapeutic for trigeminal nerve-induced neurovascular reflexes. In addition, it acts as a putative migraine prophylactic agent containing an unique stereospecific binding site in the brain.

in vitro

topiramate targets multiple cortical and subcortical loci, altering voltage-gated ion channels and chemical transmission to decrease abnormal brain excitability. preclinical studies have identified four properties that may account for the drug’s efficacy in epilepsy and migraine prophylaxis: (i) blockage of voltage-dependent sodium channels; (ii) augmentation of the activity of the neurotransmitter g-aminobutyric acid (gaba) at some subtypes of the gaba-a receptor; (iii) antagonism of the ampa/kainate subtype of the glutamate receptor; and (iv) inhibition of the carbonic anhydrase enzymes, particularly isozymes ii and iv [1].

in vivo

tonabersat binds selectively to a unique site in the brain. moreover, tonabersat could markedly reduce cortical spreading depression (csd) and csd-associated events and inhibite gap-junction communication between neurons and satellite glial cells in the trigeminal ganglion. together, these findings indicate that tonabersat should have clinical application in preventing migraine attacks [2].

References

[1] silberstein sd. tonabersat, a novel gap-junction modulator for the prevention of migraine. cephalalgia. 2009;29 suppl 2:28-35.
[2] durham pl, garrett fg. neurological mechanisms of migraine: potential of the gap-junction modulator tonabersat in prevention of migraine. cephalalgia. 2009;29 suppl 2:1-6.
[3] hauge aw, asghar ms, schytz hw, christensen k, olesen j. effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. lancet neurol. 2009;8(8):718-23.

TONABERSAT(175013-84-0)Related Product Information

• 3-CHLORO-4-FLUOROBENZAMIDE
• 2,2-DIMETHYLCHROMANE-6-CARBALDEHYDE
• (R)-1-(2-Methoxyphenyl)ethylamine
• 3-M-TOLYL-DL-BETA-ALANINOL
• 3-Chloro-4-fluorobenzylamine
• 3-Chloro-4-fluorobenzaldehyde
• (R)-m-Methyl-a-phenethylamin
• 2H-1-Benzopyran-4-amine,3,4-dihydro-,(4R)-(9CI)
• CHEMBRDG-BB 4004528
• CHEMBRDG-BB 5942726
• (R)-(+)-N-BENZOYL-ALPHA-METHYLBENZYLAMINE
• N-(4-fluorobenzyl)-N-(1-phenylethyl)amine
• TONABERSAT
• 6-METHYL-CHROMAN-4-YLAMINE HYDROCHLORIDE
• (S)-(-)-1-BENZYLAMINO-3-PHENOXY-2-PROPANOL
• CHEMBRDG-BB 4004364
• CHROMAN-4-YL-AMMONIUM CHLORIDE
• (R)-(+)-N-BENZYL-1-PHENYLETHYLAMINE HYDROCHLORIDE